Analytic Aspects of Monitoring Therapy with Thiopurine Medications
Authors:
- Victor W. ArmstrongVictor W. Armstrong
- Maria ShipkovaMSMaria Shipkova
- Nicolas von AhsenNANicolas von Ahsen
- Michael OellerichMOMichael Oellerich
- 1 April 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 26 (2) , 220-226
Abstract
The thiopurine medications 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine are used in treatment of childhood acute lymphoblastic leukemia, autoimmune diseases, and, in the case of azathioprine, in solid organ transplantation. They are converted in vivo to the active 6-thioguanine nucleotides (6-TGN). One person in 300 in white populations has low or undetectable TPMT activity and is at risk for accumulating 6-TGN with the consequence of severe, life-threatening myelosuppression. A rational therapeutic strategy for thiopurine drug use is to first determine TPMT phenotype/genotype and then to adjust the dosage on an individual basis. Determination of erythrocyte 6-TGN levels can further help to optimize therapy. TPMT activity (phenotype) is determined in erythrocytes using radiochemical or HPLC procedures. Recent HPLC procedures show good agreement with the original radiochemical method, while offering simplified sample pretreatment and improved precision. To date, 12 mutant alleles responsible for TPMT deficiency have been published. Restriction fragment length polymorphism PCR and allele-specific PCR have been used for detection of TPMT mutations. Genotyping methods that allow a higher throughput include real-time PCR (LightCycler) and denaturing HPLC. Numerous HPLC methods have been reported for quantification of 6-TGN. The majority involve acid hydrolysis to 6-TG at high temperature. There are substantial differences in the hydrolysis step, extraction procedure, chromatographic conditions and method of detection. Erythrocyte 6-TGN concentrations can vary up to 2.6-fold depending on the HPLC method. The method that has found the greatest application in clinical studies is that of Lennard. 46 This has served as the basis for the establishment of treatment-related therapeutic ranges for thiopurine therapy. These ranges will not necessarily be applicable when other methodology is used. There is an urgent need to harmonize the analytic procedures for 6-TGN.Keywords
This publication has 44 references indexed in Scilit:
- A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALLLeukemia, 2003
- The Effect of Thiopurine Methyltransferase Expression on Sensitivity to Thiopurine DrugsMolecular Pharmacology, 2002
- Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel DiseaseClinical Pharmacokinetics, 2001
- Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel diseaseGastroenterology, 2000
- Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemiaLeukemia, 2000
- Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interactionClinical Pharmacology & Therapeutics, 1997
- Thiopurine methyltransferase activity in American white subjects and black subjectsClinical Pharmacology & Therapeutics, 1994
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical propertiesClinica Chimica Acta, 1978
- Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotidesBiochemical Pharmacology, 1969